MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-12-2026
DexCom Retained Earnings 2011-2026 | DXCM
Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.Possible uses include
- reinvestment in development (R&D, equipment, marketing)
- debt repayment
- acquisition of other companies
- creation of reserves for the future
A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.
The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.
Annual Retained Earnings DexCom
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.43 B | 1.6 B | 1.02 B | 480 M | 139 M | -78.2 M | -696 M | -799 M | -672 M | -621 M | -555 M | -498 M | -475 M | -446 M | -391 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.43 B | -799 M | 29.4 M |
Quarterly Retained Earnings DexCom
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.88 B | 1.7 B | 1.6 B | 1.45 B | 1.31 B | 1.17 B | 1.02 B | 765 M | 644 M | 528 M | 480 M | 388 M | - | 236 M | 139 M | -28 M | -98.9 M | -162 M | -78.2 M | -202 M | -202 M | -202 M | -696 M | -696 M | -696 M | -696 M | -799 M | -799 M | -799 M | -799 M | -672 M | -672 M | -672 M | -672 M | -621 M | -621 M | -621 M | -621 M | -555 M | -555 M | -555 M | -555 M | -498 M | -498 M | -498 M | -498 M | -475 M | -475 M | -475 M | -475 M | -446 M | -446 M | -446 M | -446 M | -391 M | -391 M | -391 M | -391 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.88 B | -799 M | -145 M |
Retained Earnings of other stocks in the Diagnostics research industry
| Issuer | Retained Earnings | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
-62.9 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Trinity Biotech plc
TRIB
|
10.6 M | $ 0.73 | -1.86 % | $ 61.9 M |  Irlanda |
|
Akumin
AKU
|
-280 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Aspira Women's Health
AWH
|
-499 M | - | -6.19 % | $ 10.5 M |  USA |
 |
Burning Rock Biotech Limited
BNR
|
-2.23 B | $ 29.0 | -3.07 % | $ 316 M |  China |
 |
Brainsway Ltd.
BWAY
|
-77.3 M | $ 23.87 | -0.13 % | $ 99.4 M |  Israel |
 |
Accelerate Diagnostics
AXDX
|
-607 M | - | -61.36 % | $ 2.46 M | USA |
 |
Biocept
BIOC
|
-298 M | - | -13.05 % | $ 7.29 M | USA |
 |
BioNano Genomics
BNGO
|
-693 M | $ 1.14 | -2.16 % | $ 1.45 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
-84 M | - | - | $ 562 M |  Britain |
 |
Chembio Diagnostics
CEMI
|
-154 M | - | 0.22 % | $ 16.8 M | USA |
 |
Check-Cap Ltd.
CHEK
|
-170 M | - | - | $ 9.42 M | Israel |
 |
Celcuity
CELC
|
-272 M | $ 104.95 | -1.72 % | $ 4.14 B | USA |
 |
Co-Diagnostics
CODX
|
4.6 M | - | - | $ 79.8 M | USA |
 |
Danaher Corporation
DHR
|
44.2 B | $ 210.56 | -0.33 % | $ 154 B | USA |
 |
Castle Biosciences
CSTL
|
-200 M | $ 29.41 | -6.17 % | $ 817 M | USA |
 |
Global Cord Blood Corporation
CO
|
2.89 B | - | - | $ 399 M | China |
 |
Fluidigm Corporation
FLDM
|
-624 M | - | 1.08 % | $ 308 M | USA |
 |
Quest Diagnostics Incorporated
DGX
|
9.36 B | $ 202.21 | -0.11 % | $ 22.4 B | USA |
 |
Genetic Technologies Limited
GENE
|
-150 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
-4.94 B | - | 0.12 % | $ 80.1 M | China |
 |
PRA Health Sciences, Inc.
PRAH
|
440 M | - | - | $ 10.7 B | USA |
 |
DarioHealth Corp.
DRIO
|
-349 M | $ 11.75 | 2.8 % | $ 333 M | Israel |
 |
CareDx, Inc
CDNA
|
-678 M | $ 18.83 | -5.23 % | $ 1.01 B | USA |
 |
DermTech
DMTK
|
-424 M | - | -11.32 % | $ 2.94 M | USA |
 |
Enzo Biochem
ENZ
|
-294 M | - | -8.98 % | $ 14.8 K | USA |
 |
Illumina
ILMN
|
-1.24 B | $ 117.53 | -2.06 % | $ 18.7 B | USA |
 |
Fulgent Genetics
FLGT
|
590 M | $ 23.18 | -0.39 % | $ 701 M | USA |
 |
Exact Sciences Corporation
EXAS
|
-4.71 B | $ 103.45 | 0.15 % | $ 19.5 B | USA |
 |
Lantheus Holdings
LNTH
|
446 M | $ 74.31 | 1.54 % | $ 5.14 B | USA |
 |
Guardant Health
GH
|
-2.99 B | $ 103.36 | -2.84 % | $ 13 B | USA |
 |
Heska Corporation
HSKA
|
-169 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
-230 M | - | -20.0 % | $ 1.06 M | USA |
 |
ICON Public Limited Company
ICLR
|
2.72 B | $ 99.61 | 1.22 % | $ 8.22 B | Irlanda |
 |
Interpace Biosciences
IDXG
|
-235 M | $ 1.85 | 2.78 % | $ 8.12 M | USA |
 |
QIAGEN N.V.
QGEN
|
2.45 B | - | - | $ 10.6 B |  Niderland |
 |
Charles River Laboratories International
CRL
|
1.39 B | $ 169.68 | 3.11 % | $ 8.41 B | USA |
 |
IDEXX Laboratories
IDXX
|
5.33 B | $ 635.6 | 0.77 % | $ 52.4 B | USA |
 |
IQVIA Holdings
IQV
|
7.42 B | $ 166.19 | -1.87 % | $ 28.6 B | USA |
|
Biodesix
BDSX
|
-462 M | $ 13.26 | 4.0 % | $ 1.72 B | USA |
 |
Quidel Corporation
QDEL
|
945 M | $ 22.47 | -4.85 % | $ 947 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
8.3 B | $ 283.38 | 0.32 % | $ 23.8 B | USA |
 |
Biomerica
BMRA
|
-53.2 M | $ 2.17 | -2.25 % | $ 4.98 M | USA |
 |
Bioventus
BVS
|
-322 M | $ 8.57 | -0.06 % | $ 537 M | USA |
 |
Medpace Holdings
MEDP
|
-460 M | $ 452.99 | 1.47 % | $ 13.1 B | USA |
 |
Motus GI Holdings
MOTS
|
-154 M | - | -34.28 % | $ 263 K | Israel |
 |
National Research Corporation
NRC
|
-30.5 M | $ 13.65 | 9.64 % | $ 335 M | USA |
 |
Mettler-Toledo International
MTD
|
9.24 B | $ 1 378.44 | 0.14 % | $ 28.4 B |  Schweiz |